Q4 and Full Year 2024 Financial Results Appendix



Alnylam Pharmaceuticals, Inc.

Reconciliation of Selected GAAP Measures to Non-GAAP Measures (In thousands)

	,	Three Months Ended December 31,				Twelve Months Ended December 31,			
		2024		2023		2024		2023	
Reconciliation of GAAP to Non-GAAP research and development:									
GAAP Research and development	\$	300,169	\$	272,141	\$	1,126,232	\$	1,004,415	
Less: Stock-based compensation expenses		(40,625)		(19,085)		(127,749)		(97,273)	
Non-GAAP Research and development	\$	259,544	\$	253,056	\$	998,483	\$	907,142	
Reconciliation of GAAP to Non-GAAP selling, general and administrative:									
GAAP Selling, general and administrative	\$	295,339	\$	198,123	\$	975,526	\$	795,646	
Less: Stock-based compensation expenses		(51,020)		(22,909)		(144,335)		(124,407)	
Non-GAAP Selling, general and administrative	\$	244,319	\$	175,214	\$	831,191	\$	671,239	
Reconciliation of GAAP to Non-GAAP operating loss:									
GAAP operating loss	\$	(105,159)	\$	(116,404)	\$	(176,885)	\$	(282,175)	
Add: Stock-based compensation expenses		91,645		41,994		272,084		221,680	
Non-GAAP Operating (loss) income	\$	(13,514)	\$	(74,410)	\$	95,199	\$	(60,495)	



Alnylam Pharmaceuticals, Inc.

Reconciliation of Product Revenue and Growth at Constant Currency

	December	December 31, 2024			
	Three Months Ended	Twelve Months Ended			
Total TTR net product revenue growth, as reported	35 %	34 %			
Add: Impact of foreign currency translation	(1)				
Total TTR net product revenue growth at constant currency	34 %	34 %			
Total Rare net product revenue growth, as reported	18 %	29 %			
Add: Impact of foreign currency translation	(1)	(1)			
Total Rare net product revenue growth at constant currency	17 %	28 %			
Total net product revenue growth, as reported	30 %	33 %			
Add: Impact of foreign currency translation	(1)				
Total net product revenue growth at constant currency	29 %	33 %			
Total revenue growth, as reported	35 %	23 %			
Add: Impact of foreign currency translation	(1)				
Total revenue growth at constant currency	34 %	23 %			



Please note that the figures presented above may not sum exactly due to rounding Constant Currency = Constant Exchange Rate, or CER

29